Venture capital titan Sequoia China led a multimillion-dollar Angel funding round for brain-computer interface (BCI) startup Tianfukang Medical Technology Co. Ltd., signaling surging private capital confidence as Chinese neurotech developers shift from laboratory breakthroughs to commercial human trials.
The investment, which included participation from the Yuanming Neuroscience Fund, marks the second major capital injection in six months for the one-year-old Beijing startup. Tianfukang previously secured early-stage backing from Fosun Pharma's Fuxian Capital Star Venture Fund in March 2026. The capital expansion comes as China elevated brain-computer interface technology to a strategic priority in its 2026 national economic planning, designating neurotech as a key industry of the future.
Tianfukang is developing a proprietary closed-loop neuromodulation platform that targets specific peripheral nerve bundles rather than broad nerve trunks or general tissue. By pairing flexible, self-coiling electrodes with dedicated BCI processors and adaptive algorithms, the company's lead system decodes motor intent in post-stroke patients with upper-limb paralysis and translates those signals into targeted electrical stimulation to restore fine finger and hand movements.
In non-human primate trials, Tianfukang's system successfully enabled subjects to execute complex grip and extension tasks, fulfilling criteria under standard upper-extremity motor assessment frameworks. To accelerate clinical translation, the startup established a joint laboratory with Beijing Tiantan Hospital, allowing engineering teams to refine algorithms and hardware based on direct feedback from neurosurgical clinicians.
The commercial investment coincides with major clinical milestones across Chinese research hospitals. Neurosurgeons at the First Affiliated Hospital of Harbin Medical University in Heilongjiang province successfully implanted a fully wireless, neuron-level invasive BCI system into a 56-year-old patient suffering from quadriplegia caused by a severe cervical spinal cord injury.
Led by Professor Shi Huaizhang, the surgical team deployed ultra-thin, micron-level flexible electrodes capable of capturing electrophysiological signals from individual neurons without significant tissue damage. The fully implanted wireless transceiver operates via an internal rechargeable battery, eliminating external wiring and allowing the patient to calibrate hand-movement intent through screen-based feedback as part of a multi-disciplinary rehabilitation program.
The wireless system implanted in Harbin previously underwent landmark clinical evaluations, including an August 2025 deep-brain tumor boundary mapping trial conducted with the Chinese Academy of Sciences Aerospace Information Research Institute. In May 2026, Beijing Tiantan Hospital initiated a multi-center clinical trial evaluating the same architecture for paralyzed spinal cord injury patients.
Simultaneously, established Chinese medical device manufacturers are expanding their footprints across non-invasive, interventional, and invasive neurotech markets. Medical giant Lepu Medical confirmed that its interventional multi-channel BCI product completed preclinical animal testing and advanced into human investigator-initiated clinical trials, while its approved implantable deep brain stimulator system entered commercial hospital networks across multiple provinces.
